Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | CA7 | P43166 | 1/20 | 0.63 |
| ▸ | CA9 | Q16790 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | SCN1A | P35498 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8795711 | 0.92 | HRH3 (0.70) | LTA4HHRH3ALDH1A1MAPK1CYP1A2 | |
| SCHEMBL8795140 | 0.91 | ALDH1A1 (0.64) | LTA4HHRH3ALDH1A1MAPK1CYP1A2 | |
| SCHEMBL23963216 | 0.88 | LTA4H (0.66) | LTA4HCA12CA1CA2CA7 | |
| SCHEMBL109617 | 0.85 | LTA4H (0.59) | LTA4HNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL6947417 | 0.85 | PSMB1 (0.73) | LTA4HHRH3 | |
| SCHEMBL2249548 | 0.84 | LTA4H (0.69) | LTA4HCA12CA1CA2CA7 | |
| SCHEMBL4485540 | 0.84 | LTA4H (0.69) | LTA4HCA12CA1CA2CA7 | |
| SCHEMBL874183 | 0.84 | LTA4H (0.61) | LTA4HCA12CA1CA2CA7 | |
| SCHEMBL374497 | 0.84 | LTA4H (0.67) | LTA4HCA12CA1CA2CA7 | |
| SCHEMBL224640 | 0.84 | PSMB1 (0.76) | LTA4HHRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036650-A1 | Compounds and methods for peptide synthesis | BIOGEN IDEC MA INC. | 2009-02-05 | — | — | US | claimed |
| EP-1869088-A2 | COMPOUNDS AND METHODS FOR PEPTIDE SYNTHESIS | Biogen Idec MA Inc. (US) | 2007-12-26 | — | — | EP | claimed |
| WO-2006104922-A2 | COMPOUNDS AND METHODS FOR PEPTIDE SYNTHESIS | BIOGEN IDEC MA INC. (US) | 2006-10-05 | — | — | WO | claimed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2025-01-16 | — | — | US | disclosed |
| EP-4474383-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2024-12-11 | — | — | EP | disclosed |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-11897864-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20240043404-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2024-02-08 | — | — | US | disclosed |
| EP-2435432-B3 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE IRELAND UNLIMITED CO (BM) | 2023-10-25 | — | — | EP | disclosed |
| WO-2008009077-A2 | 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008009078-A2 | 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008009076-A2 | SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008003149-A2 | SUBSTITUTED PTERIDINES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES , INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| EP-1869088-A2 | COMPOUNDS AND METHODS FOR PEPTIDE SYNTHESIS | Biogen Idec MA Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006104922-A2 | COMPOUNDS AND METHODS FOR PEPTIDE SYNTHESIS | BIOGEN IDEC MA INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| US-6008226-A | AN ENZYME INHIBITOR OF C-GMP-PHOSPHODIESTERASE FOR TREATING HEART FAILURE, HYPERTENSION, REVERSING OR REDUCING NITRATE-INDUCED TOLERANCE AND ANGINA PECTORIS, CONGESTIVE HEART DISEASE AND MYOCARDIAL INFARCTION | SANOFI-SYNTHELABO (FR) | 1999-12-28 | — | — | US | disclosed |
| US-5614530-A | GMP PHOSPHODIESTERASE INHIBITOR, HYPOTENSIVE | STERLING WINTHROP INC. (US) | 1997-03-25 | — | — | US | disclosed |
| WO-1996028159-A1 | SUBSTITUTED N-ARYLMETHYL AND HETEROCYCLYLMETHYL-1H-PYRAZOLO[3,4-b]QUINOLIN-4-AMINES AND COMPOSITIONS AND METHODS OF USE THEREOF | SANOFI WINTHROP, INC. (US) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | LTA4H 2159/4885CA12 4586/4885CA1 4666/4885 |
| US-20090036650-A1 | Compounds and methods for peptide synthesis | PTMS, NPPA, DNPEP | LTA4H 2593/4885CA12 1871/4885CA1 818/4885 |
| US-11897864-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | BCL2, BAX, BCL3 | LTA4H 3496/4885CA12 1381/4885CA1 1508/4885 |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | LTA4H 3496/4885CA12 1381/4885CA1 1508/4885 |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | LTA4H 4714/4885CA12 2561/4885CA1 2706/4885 |
| US-20240043404-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | LTA4H 3496/4885CA12 1381/4885CA1 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.